The case for & against
Bull & Bear analysis
Bearish
Moderna, Inc. (NASDAQ: MRNA) is a leading biotechnology company focused on mRNA technology for developing transformative vaccines and therapeutics targeting infectious diseases, oncology, and rare diseases. Initially recognized for its COVID-19 vaccine, the company is expanding its portfolio to include respiratory vaccines and cancer treatments, positioning itself strategically within the evolving bioscience landscape and aiming for significant growth as it transitions from pandemic reliance to a diversified therapeutic pipeline.
Bull says
- ↑Q1’26 revenue $400M (+300% YoY) led by partnerships and intl sales
- ↑$7.5B cash & investments secures liquidity for R&D and ops
- ↑EU approval of mCombriax positions first flu-COVID combo for 2027 launch
- ↑26% YoY reduction in adjusted cash costs reflects disciplined cost cuts
- ↑Entismeran NSCLC oncology candidate offers multibillion-dollar upside
- ↑Strong momentum and liquidity factors signal stable fundamentals
Bear says
- ↓Q1’26 net loss $1.3B driven by litigation settlements and high opex
- ↓COVID vaccine sales decline weighing on near-term revenue outlook
- ↓US FDA uncertainty may delay key vaccine and therapy approvals
- ↓Intense vaccine competition pressures pricing amid lower vaccination rates
- ↓Potential $1.3B in legal payouts strains future cash flow
- ↓Weak profitability and growth factors underline recovery challenges
Investment themes with MRNA
High Beta↓ -0.12%
Stocks with high volatility relative to market
AMD · DELL · MPWR
Biotech↓ -3.20%
Genetic and drug innovations driving medical breakthroughs
APLS · RVMD · SMMT
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-02-2026neutral
Transcript signals
Bull points
- For the first quarter, total revenue was $400 million, coming in above our guidance and represents a $300 million increase versus the prior year.
- Our strong revenue performance year-to-date puts us on a solid path to achieve our full-year revenue growth target of up to 10 percent, which we are reiterating today.
- Our 2026 revenue guidance factors in potential future declines in COVID vaccination rates, offset by increased penetration of MNIC spike, and revenue from our long-term strategic partnerships.
Bear points
- Net loss for the quarter was $1.3 billion, or $3.40 per share, compared to a net loss of $1 billion, or $2.52 per share last year, primarily driven by the litigation settlement.
- We have concluded that a loss related to this pending Section 1498 proceeding is not probable, and accordingly, no charge has been recorded.
- We do not expect revenues in the year of approval for these vaccines.
Read full transcript analysis ›